Stocks in play: MYND Life Sciences
Announced positive preclinical data in measuring dosing accuracy in psilocybins and psilocybin analogs. Today, Mynd announces substantial advances in creating a molecular test for calibrating and measuring cellular responses to microdosing with psilocybin. MYND Life Sciences shares C.MYND are trading up $0.02 at $0.07.
Read:
Innovative Food Stocks Responding to Conflict-, and Drought-Driven Food Supply Shocks
Crypto Miners Finding Success While Shifting Towards Environmentally Sustainable Operations
New Approaches Towards Immunotherapy Give Hope in Fight Against Solid Tumors
As a Major Social Media Shuffle Looms, Uptake and Value of Dogecoin (DOGE) Surges
New Regions Being Developed to Produce More Oil Amid Government’s Calls for More Output